source
- Capricor boosts manufacturing capacity as FDA decision on DMD cell therapy loomsCapricor Therapeutics, a biotech developing a cell therapy for Duchenne muscular dystrophy, is preparing for an FDA decision expected by late November. The company’s third-quarter operating expens…
- BioNTech spends $205 million on FDA priority review voucher to accelerate oncology pipelineBioNTech has agreed to pay $205 million to acquire an FDA priority review voucher, a tool that can shorten the agency's standard review period from ten months to six months. The voucher was previo…